Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Leukemia
|
October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
R F Schlenk, F Stegelmann, A Reiter, et al.
Leukemia
|
November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
U Platzbecker, H K Al-Ali, N Gattermann, et al.
Journal of Hematology & Oncology
|
March 6, 2016
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A Kaifie, M Kirschner, D Wolf, et al.
Leukemia
|
July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Leukemia
|
February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A Hochhaus, T Masszi, F J Giles, et al.
Leukemia
|
April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
W Ingram, N C Lea, J Cervera, et al.
Leukemia
|
January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
K Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia
|
October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
M C Müller, N Gattermann, T Lahaye, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Leukemia
|
October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
R F Schlenk, F Stegelmann, A Reiter, et al.
Leukemia
|
November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
U Platzbecker, H K Al-Ali, N Gattermann, et al.
Journal of Hematology & Oncology
|
March 6, 2016
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A Kaifie, M Kirschner, D Wolf, et al.
Leukemia
|
July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Leukemia
|
February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A Hochhaus, T Masszi, F J Giles, et al.
Leukemia
|
April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
W Ingram, N C Lea, J Cervera, et al.
Leukemia
|
January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
K Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia
|
October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
M C Müller, N Gattermann, T Lahaye, et al.
Page
of 11